Nevertheless, the pathogenesis of MEK-inhibitor-associated retinopathy is still unclear, and questions are still open about the possible toxicity related to different new types of MEK inhibitors, used alone or in combination with BRAF inhibitors, or on the possible involvement of the chorioretinal vascular network in this process, as we observe during CSCR. Here, MAP2K7 is linked to retinal disorder.